[Chemotherapy and targeted therapy of head and neck squamous cell carcinomas at the 2021 ASCO meeting].

Patient-specific and possibly local application of cisplatin might be considered in the future. Moreover, mHRAS inhibition might also be useful for selected patients after sequencing.